Elevated anticardiolipin antibodies in acute liver failure  by Rozee, K.R. et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1637 (2003) 183–186Rapid report
Elevated anticardiolipin antibodies in acute liver failure
K.R. Rozeea, P. Acottb,c, S.H.S Leea, J.F.S. Crockerb,c, D. Gougha, J. MacDonalda,
J. Evansd, M.G. Murphyd,*
aDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7
bDepartment of Pediatrics, Dalhousie University Halifax, Nova Scotia, Canada B3J 3G9
c IWK Health Centre, Halifax, Nova Scotia, Canada B3J 3G9
dDepartment of Physiology and Biophysics, Dalhousie University, Sir Charles Tupper Medical Building, Halifax, Nova Scotia, Canada B3H 4H7Received 30 December 2002; received in revised form 4 February 2003; accepted 27 February 2003Abstract
Antibodies to cardiolipin (aCLA), a phospholipid primarily localized in inner mitochondrial membranes, were transiently elevated
(P < 0.01) when mice were exposed to an industrial surfactant and then infected with influenza B virus, a model of acute liver failure (ALF).
Children with ALF also had elevated levels of aCLA.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Anticardiolipin antibody; Acute liver failure; Reye’s syndrome; Surfactant/influenza B mouse modelCardiolipin (diphosphatidylglycerol), a very minor com-
ponent of most mammalian membranes, but a major compo-
nent of inner mitochondrial membranes [1], initiates an
antibody response in a variety of diseases involving mito-
chondrial damage. It has long been known that patients with
autoimmune diseases (e.g., systemic lupus erythematosus
[SLE], rheumatoid arthritis) and thromboembolic diseases
(e.g., stroke, myocardial infarction) regularly produce high
levels of anticardiolipin antibodies (aCLA) [2]. However,
aCLA have also been shown to be elevated in the absence of
systemic disease, in patients taking various drugs (e.g.,
valproate, phenytoin) or with a spectrum of viral infections
(e.g., hepatitis C, varicella zoster) [2,3]. Increases in aCLA
have also been observed in SLE patients following vaccina-
tion with inactivated influenza [4] and in patients with
Sjo¨gren’s syndrome following infection with influenza A [5].
Acute liver failure (ALF), one example of which is
Reye’s syndrome (RS), appears to be an injury cascade that
leads to derangement of hepatic mitochondrial membranes
and organelle dysfunction [6]. It is a heterogeneous syn-
drome that may result from an interaction between viruses
such as influenza B (FluB) and one or more xenobiotic0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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E-mail address: mary.murphy@dal.ca (M.G. Murphy).chemicals including aspirin, valproic acid and industrial
surfactants [7]. The mechanism(s) underlying ALF have
not been identified, although energy metabolism appears to
be severely compromised both in humans and in animal
models [7]. As we have demonstrated that there is extensive
mitochondrial damage in our surfactant/FluB mouse model
of ALF (Fig. 1), we proposed that aCLA would be elevated
in this model. To test this hypothesis, we analyzed aCLA
levels in sera from mice at various times throughout the in
vivo experiment. As well, archived sera from five children
with symptoms consistent with ALF, and six non-ALF
patients of similar ages were analyzed for aCLA.
The surfactant/FluB mouse model, which reproduces
many of the features of human ALF, has been described
previously [7]. Briefly, neonatal mice were dermally
exposed to either minimal essential media (MEM, vehicle
control) or a dilute solution of the industrial surfactant,
Toximul (Tox), daily for 12 days. On postnatal (P) day 13
(P13), half of each group were lightly anaesthetized with
ether and inoculated with a sublethal dose (LD10–20) of
mouse-adapted FluB. The remainder were anaesthetized
only. Deaths in the four experimental groups (MEM, Tox,
FluB, Tox + FluB) were recorded daily until P21 when
remaining animals were killed. At the times of sacrifice,
bloods were collected and sera were separated and stored at
 86 jC until analysis. aCLA were analyzed using two
methods. The first was an in-house, solid phase enzymeed.
Fig. 1. Electron microscopic assessment (17,000 magnification) of livers from control (MEM) and Tox + FluB-treated mice on experimental day 17 (P17).
Mice were exposed to Tox and subsequently infected with FluB as described in the text. The livers of the treated mice showed prominent cytoplasm typical of
cellular swelling, disorganization of the endoplasmic reticulum, and distorted mitochondria with poorly defined cristae.
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culture plates were coated with cardiolipin (45 Ag/ml in
ethanol), the solvent was dried under N2, and the wells were
washed with 0.3% gelatin in phosphate-buffered saline, pH
7.2 (gel-PBS). Sera (50 Al) were added to the wells and the
plates were incubated at 37 jC for 90 min. After the wells
were washed (gel-PBS followed by 1% bovine serum
albumin in gel-PBS), goat anti-mouse or anti-human IgG
tagged with alkaline phosphatase (AP) was added for 90
min. The plates were washed and AP substrate ( p-nitro-
phenyl phosphate disodium, 100 Al, Sigma-Aldrich) was
added to each well. After 30 min, the reactions were stopped
with 50 Al of 20 nM cysteine. Optical densities were read at
410/490 nm on a microplate reader (DYNEX Technologies
Inc., Chantilly, VA). The second method was done using an
aCLA ELISA kit from Alpha Diagnostic International (San
Antonio, TX). The data are expressed as the ratio of optical
densities in test wells relative to control wells without
serum. Values for the different experimental groups of mice
are presented relative to standardized MEM controls ( = 1.0).
Statistical analysis was done using a Student’s unpaired t-test
with Bonferroni correction for multiple testing.
The results of the mouse sera analyses are illustrated in
Fig. 2. Two days following FluB inoculation (P15) and
before any mice had died (Fig. 2A), levels of aCLA in mice
treated with Tox alone were elevated by c 20%, an effect
that persisted until P17, 5 days after painting had ceased
(Fig. 2B). The aCLA-elevating effect of Tox had waned by
P21. In mice only infected with FluB, aCLA levels were
increased also by c 20%; however, the effect was not
observed until P17, and persisted until at least 8 days after
inoculation (P21). The most noteworthy finding was that on
P17, aCLA levels in mice treated with both Tox and FluB
were >100% higher than values for the MEM group(P < 0.005) and significantly higher than values for either
the Tox alone (P < 0.002) or FluB alone (P < 0.02) groups.
This effect coincided with the onset of mortality (Fig. 2A)
and was transient in nature. Values for aCLA in the
Tox + FluB group were equivalent to those for Tox alone
on P15, and to those for FluB alone on P21. The mean
value (F S.E.) for aCLA in archived sera from children
diagnosed with ALF (three RS, one medium chain acyl-
CoA dehydrogenase deficiency, one toxic encephalopathy)
was >250% higher than in non-ALF patients of similar
ages (P= 0.03) (Fig. 3).
Infection-induced increases in aCLA expression, in con-
trast to patterns seen in autoimmune diseases, tend to be
relatively minor and transient [2,3,9]. This may be related to
the fact that infection-related aCLA bind directly to cardi-
olipin, while those associated with autoimmune diseases
bind tightly to a cofactor protein [1,2,10]. The clinical
significance of aCLA in virus and drug settings is not
known. While the elevations in autoimmune disease [2,9]
and in some viral infections [3] are associated with
increased risk of thrombosis, those in other diseases are
believed to be nonspecific reflections of liver damage [10].
Consistent with the latter, the ALF patients whose sera had
elevated aCLA (Fig. 3) had no history of thrombosis, yet
had evidence of hepatic damage.
Our studies have shown that mice exposed to the
presumed nontoxic industrial surfactant, Tox, and then
infected with low doses of FluB have marked degeneration
of hepatic mitochondria (Fig. 1) and significant transient
increases in ammonia production [11]. In the present study,
we observed that without Tox exposure, there were modest
(c 20%) elevations in aCLA 4 days after the mice were
inoculated with the respiratory FluB virus. While the lung is
a presumed site of the cardiolipin stimulus, other sites are
Fig. 2. Mortality and aCLA levels in the Tox + FluB mouse model of ALF. Mice were treated with MEM (control), Tox, FluB or Tox + FluB as described in the
text. (A) Mean numbers of deaths that occurred up to P21 in mice only infected with FluB and in mice exposed to Tox and then infected with FluB in three
separate in vivo experiments. Insert: Time courses of deaths in the Tox + FluB group in individual experiments. (B) Sera were collected at P15, P17 and P21
and were analyzed for aCLA as described in the text. Data are the meansF S.E. of standardized values from 4 to 12 mice in each group on each sampling day.
*Data were significantly higher than all other experimental groups ( P < 0.01) on P17.
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muscle [12], in brains of children with influenza A- and B-
associated encephalopathy [13], and in livers of experimen-
tal animals [14,15]. This study showed that exposing young
mice to Tox and then infecting them with FluB increased
aCLA levels by 100% (Fig. 2B). A Tox-alone effect,
although modest, preceded this interactive reaction, suggest-
ing that surfactant exposure was an obligate partner.
Although the significance of the synergistic, Tox + FluB-mediated elevation in aCLA is not known, it is consistent
with our previous demonstration that energy metabolism
is severely compromised in this model [7]. Cardiolipin
plays an intimate, essential role in many aspects of
mitochondrial energy production [1], including carnitine-
dependent transport of fatty acids across the mitochon-
drial membrane. Our earlier studies demonstrated that the
modest inhibitions of fatty-acid h-oxidation with Tox or
FluB treatments individually were potentiated when the
Fig. 3. aCLA levels in archived sera from children diagnosed with ALF and from age-matched controls. Sera were analyzed for aCLA as described in the text.
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inhibition of h-oxidation was due solely to blockade of
mitochondrial matrix events. However, the disruptions in
mitochondrial membrane integrity suggested by the dem-
onstrated elevations in circulating aCLA in this study
lend support to the possibility that transport of fatty acids
into the mitochondria is also compromised.References
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